Luke Whitesell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luke Whitesell has a total of 207 co-authors. Here are the top co-authors by number of shared publications:
Susan Lindquist
23 shared publicationsAlex M. Jaeger
22 shared publications- Sandro Santagata
Department of Pathology, Brigham and Women’s Hospital, Boston, MA 02115, USA
22 shared publications - Demi Sandel
Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
21 shared publications - Giorgio Gaglia
Brigham and Women's Hospital, Harvard Medical School
21 shared publications Jane B. Trepel
21 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (11)
A randomized phase II study of fulvestrant with or without ganetespib in patients with endocrine-resistant metastatic breast cancer
Background: Patients with endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative metastatic breast cancer (MBC) have limited effective treatment options. Heat shock protein 90 (HSP90) regulates estrogen receptor stability and function; its inhibition has been proposed as a strategy to overcome endocrine resistance. Ganetespib is a second-generation HSP90 inhibitor with demonstrated anti-tumor activity in preclinical breast cancer models. Methods: In this randomized phase II study, 50 patients with HR+ MBC previously treated with endocrine therapy were randomized 1:2 to fulvestrant alone (n = 15) or fulvestrant with ganetespib (n = 35), respectively. Median age was 53 years. Fulvestrant was administered at standard dosing; ganetespib (200 mg/m2) was given intravenously on days 1, 8, and 15 of each 28-day cycle. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival and safety/tolerability. Results: Median PFS was similar between arms (3.7 vs 3.6 months; log-rank P = .79). Toxicity was higher with ganetespib, with substantially increased diarrhea (97% vs 7%) and nausea (63% vs 40%). Exploratory genomic analysis of on-treatment biopsies (n = 13) showed ESR1 mutations were enriched among patients without clinical benefit, while all patients with clinical benefit exhibited a Luminal A transcriptional subtype. Tumors lacking clinical benefit showed enrichment of proliferative and cell cycle–associated transcriptional programs. Conclusions: Adding ganetespib to fulvestrant did not improve clinical outcomes and increased toxicity in endocrine-resistant HR+ MBC. Our findings support the hypothesis that ESR1 alterations and proliferative transcriptional activity contribute to established endocrine resistance, limiting the therapeutic impact of HSP90 inhibition in this setting. Clinical trial registration number: NCT01560416 (ClinicalTrials.gov)
- 7 October 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (11)
Open AccessA randomized phase II study of fulvestrant with or without ganetespib in patients with endocrine-resistant metastatic breast cancer
Background: Patients with endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative metastatic breast cancer (MBC) have limited effective treatment options. Heat shock protein 90 (HSP90) regulates estrogen receptor stability and function; its inhibition has been proposed as a strategy to overcome endocrine resistance. Ganetespib is a second-generation HSP90 inhibitor with demonstrated anti-tumor activity in preclinical breast cancer models. Methods: In this randomized phase II study, 50 patients with HR+ MBC previously treated with endocrine therapy were randomized 1:2 to fulvestrant alone (n = 15) or fulvestrant with ganetespib (n = 35), respectively. Median age was 53 years. Fulvestrant was administered at standard dosing; ganetespib (200 mg/m2) was given intravenously on days 1, 8, and 15 of each 28-day cycle. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival and safety/tolerability. Results: Median PFS was similar between arms (3.7 vs 3.6 months; log-rank P = .79). Toxicity was higher with ganetespib, with substantially increased diarrhea (97% vs 7%) and nausea (63% vs 40%). Exploratory genomic analysis of on-treatment biopsies (n = 13) showed ESR1 mutations were enriched among patients without clinical benefit, while all patients with clinical benefit exhibited a Luminal A transcriptional subtype. Tumors lacking clinical benefit showed enrichment of proliferative and cell cycle–associated transcriptional programs. Conclusions: Adding ganetespib to fulvestrant did not improve clinical outcomes and increased toxicity in endocrine-resistant HR+ MBC. Our findings support the hypothesis that ESR1 alterations and proliferative transcriptional activity contribute to established endocrine resistance, limiting the therapeutic impact of HSP90 inhibition in this setting. Clinical trial registration number: NCT01560416 (ClinicalTrials.gov)
- Open Access
Structure-activity Relationship for Diarylpyrazoles as Inhibitors of the Fungal Kinase Yck2
Candida albicans is a growing global health threat, causing 1.5 million invasive infections and 1 million deaths annually. Yeast casein kinase 2 (Yck2) in C. albicans has emerged as an antifungal target of the kinase inhibitor LY364947 ( LY ). Herein, we report Yck2 structure-activity relationships for 3,4- and 3,4,5-substituted pyrazole analogs of LY . X-ray crystallography and in vitro profiling revealed the importance of the hinge-binding heterocycle for Yck2 inhibition and fungal kinome selectivity. A hydrogen-bond network between the inhibitor, a bound water molecule, and catalytic residues within the ATP pocket was identified as a key determinant of selectivity over other fungal and human kinases. Phenol analog 11 showed remarkable selectivity for Yck2 and Yck22 over all other C. albicans protein kinases. Several of the LY analogs, including 11 , demonstrated improved antifungal activity. These findings provide a framework for translating human kinase inhibitors into highly selective antifungal Yck2 inhibitors. Graphical
Open AccessStructure-activity Relationship for Diarylpyrazoles as Inhibitors of the Fungal Kinase Yck2
Candida albicans is a growing global health threat, causing 1.5 million invasive infections and 1 million deaths annually. Yeast casein kinase 2 (Yck2) in C. albicans has emerged as an antifungal target of the kinase inhibitor LY364947 ( LY ). Herein, we report Yck2 structure-activity relationships for 3,4- and 3,4,5-substituted pyrazole analogs of LY . X-ray crystallography and in vitro profiling revealed the importance of the hinge-binding heterocycle for Yck2 inhibition and fungal kinome selectivity. A hydrogen-bond network between the inhibitor, a bound water molecule, and catalytic residues within the ATP pocket was identified as a key determinant of selectivity over other fungal and human kinases. Phenol analog 11 showed remarkable selectivity for Yck2 and Yck22 over all other C. albicans protein kinases. Several of the LY analogs, including 11 , demonstrated improved antifungal activity. These findings provide a framework for translating human kinase inhibitors into highly selective antifungal Yck2 inhibitors. Graphical
- Open Access
Chemoproteomic Profiling of C. albicans for Characterization of Anti-fungal Kinase Inhibitors
Candida albicans is a growing health concern as the leading causal agent of systemic candidiasis, a life-threatening fungal infection with a mortality rate of ∼40% despite best available therapy. Yck2, a fungal casein kinase 1 (CK1) family member, is the cellular target of inhibitors YK-I-02 (YK) and MN-I-157 (MN). Here, multiplexed inhibitor beads paired with mass spectrometry (MIB/MS) employing ATP-competitive kinase inhibitors were used to define the selectivity of these Yck2 inhibitors across the global C. albicans proteome. The MIB matrix captured 89% of the known and predicted C. albicans protein kinases present in cell lysate. In MIB/MS competition assays, YK and MN demonstrated exquisite selectivity across the C. albicans fungal kinome with target engagement of only three CK1 homologs (Yck2, Yck22, and Hrr25) and a homolog of human p38α (Hog1). Additional chemoproteomics using a custom MN-kinobead identified only one additional C. albicans protein, confirming its remarkable fungal proteome-wide selectivity. To identify new Yck2 inhibitors with selectivity over Hog1, thirteen human CK1 kinase inhibitors were profiled for fungal kinase-binding activity using MIB/MS competition assays and in-cell NanoBRET target engagement assays. A new chemotype of family-selective Yck2 inhibitors with antifungal activity was identified. Together, these findings expand the application of MIB/MS proteomic profiling for non-human kinomes and demonstrate its utility in the discovery and development of selective inhibitors of fungal kinases with potential antimicrobial activity. GRAPHICAL
Open AccessChemoproteomic Profiling of C. albicans for Characterization of Anti-fungal Kinase Inhibitors
Candida albicans is a growing health concern as the leading causal agent of systemic candidiasis, a life-threatening fungal infection with a mortality rate of ∼40% despite best available therapy. Yck2, a fungal casein kinase 1 (CK1) family member, is the cellular target of inhibitors YK-I-02 (YK) and MN-I-157 (MN). Here, multiplexed inhibitor beads paired with mass spectrometry (MIB/MS) employing ATP-competitive kinase inhibitors were used to define the selectivity of these Yck2 inhibitors across the global C. albicans proteome. The MIB matrix captured 89% of the known and predicted C. albicans protein kinases present in cell lysate. In MIB/MS competition assays, YK and MN demonstrated exquisite selectivity across the C. albicans fungal kinome with target engagement of only three CK1 homologs (Yck2, Yck22, and Hrr25) and a homolog of human p38α (Hog1). Additional chemoproteomics using a custom MN-kinobead identified only one additional C. albicans protein, confirming its remarkable fungal proteome-wide selectivity. To identify new Yck2 inhibitors with selectivity over Hog1, thirteen human CK1 kinase inhibitors were profiled for fungal kinase-binding activity using MIB/MS competition assays and in-cell NanoBRET target engagement assays. A new chemotype of family-selective Yck2 inhibitors with antifungal activity was identified. Together, these findings expand the application of MIB/MS proteomic profiling for non-human kinomes and demonstrate its utility in the discovery and development of selective inhibitors of fungal kinases with potential antimicrobial activity. GRAPHICAL
- Open Access
- 27 July 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-16
Multifactor transcriptional control of alternative oxidase induction integrates diverse environmental inputs to enable fungal virulence
Metabolic flexibility enables fungi to invade challenging host environments. In Candida albicans, a common cause of life-threatening infections in humans, an important contributor to flexibility is alternative oxidase (Aox) activity. Dramatic induction of this activity occurs under respiratory-stress conditions, which impair the classical electron transport chain (ETC). Here, we show that deletion of the inducible AOX2 gene cripples C. albicans virulence in mice by increasing immune recognition. To investigate further, we examined transcriptional regulation of AOX2 in molecular detail under host-relevant, ETC-inhibitory conditions. We found that multiple transcription factors, including Rtg1/Rtg3, Cwt1/Zcf11, and Zcf2, bind and regulate the AOX2 promoter, conferring thousand-fold levels of inducibility to AOX2 in response to distinct environmental stressors. Further dissection of this complex promoter revealed how integration of stimuli ranging from reactive species of oxygen, nitrogen, and sulfur to reduced copper availability is achieved at the transcriptional level to regulate AOX2 induction and enable pathogenesis.
- 27 July 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-16
Open AccessMultifactor transcriptional control of alternative oxidase induction integrates diverse environmental inputs to enable fungal virulence
Metabolic flexibility enables fungi to invade challenging host environments. In Candida albicans, a common cause of life-threatening infections in humans, an important contributor to flexibility is alternative oxidase (Aox) activity. Dramatic induction of this activity occurs under respiratory-stress conditions, which impair the classical electron transport chain (ETC). Here, we show that deletion of the inducible AOX2 gene cripples C. albicans virulence in mice by increasing immune recognition. To investigate further, we examined transcriptional regulation of AOX2 in molecular detail under host-relevant, ETC-inhibitory conditions. We found that multiple transcription factors, including Rtg1/Rtg3, Cwt1/Zcf11, and Zcf2, bind and regulate the AOX2 promoter, conferring thousand-fold levels of inducibility to AOX2 in response to distinct environmental stressors. Further dissection of this complex promoter revealed how integration of stimuli ranging from reactive species of oxygen, nitrogen, and sulfur to reduced copper availability is achieved at the transcriptional level to regulate AOX2 induction and enable pathogenesis.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
PBMC RNAseq Raw Transcript Counts
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
PBMC RNAseq Raw Transcript Counts
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
MC38 Tumors Pan Cancer Immune Profiling Codeset
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
MC38 Tumors Pan Cancer Immune Profiling Codeset
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
PBMC RNAseq DESeq2 Data Tables
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
PBMC RNAseq DESeq2 Data Tables
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation